New Cancer Treatment Using Chemical Inducers
Author Information
Author(s): Huang Kai
Primary Institution: Department of Medical Oncology, Qilu Hospital of Shandong University
Hypothesis
Can chemically induced proximity be used to activate pro-apoptotic genes in cancer therapy?
Conclusion
The study shows that CDK-TCIPs can selectively kill BCL6-overexpressing cancer cells by activating pro-apoptotic genes.
Supporting Evidence
- CDK-TCIPs exhibited subnanomolar cytotoxicity in BCL6-driven DLBCL cells.
- CDK-TCIPs achieved approximately 100 times greater potency than traditional inhibitors of CDK9 and BCL6.
- CDK-TCIPs lead to localized phosphorylation of RNA polymerase II and activation of BCL6-repressed genes involved in apoptosis.
Takeaway
Scientists found a new way to help treat cancer by using special chemicals that can turn on genes that make cancer cells die.
Methodology
The study designed CDK-TCIPs that link inhibitors of CDK9 to ligands of the BCL6 BTB domain to activate gene expression.
Limitations
The safety profile of CDK-TCIPs needs to be evaluated in vivo, and careful dose optimization is required due to the bell-shaped dose-response curve.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website